Vimarsana
Biggest News Aggregation in the World

Page 36 - Breakthrough Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Breakthrough Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Breakthrough Therapy Today - Breaking & Trending Today

Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders - Vimarsana News

Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders

TORONTO, Dec. 20, 2023 -- Revive Therapeutics Ltd. , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to...

Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer - Vimarsana News

Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer

MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it...

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Dec. 19, 2023 -- 89bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and...

First dose of new Alzheimer's drug given in WNC, UNC Health Pardee announces - Vimarsana News

First dose of new Alzheimer's drug given in WNC, UNC Health Pardee announces

UNC Health Pardee says it's the first health care organization in Western North Carolina to administer a newly FDA-approved drug to treat Alzheimer's disease.

Source: wlos.com
Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder - Vimarsana News

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

Initial safety findings at 24 hours post dosing were consistent with studies of COMP360 in other psychiatric conditionsLONDON, Dec. 19, 2023 -- Compass Pathways plc , a biotechnology company...